Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

Patent metadata

Field	Value
Publication number	US-12496353-B2
Application number	US-202318166491-A
Country	US
Kind code	B2
Filing date	Feb 9, 2023
Priority date	Oct 22, 2010
Publication date	Dec 16, 2025
Grant date	Dec 16, 2025

Abstract

The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.

First claim

What is claimed:

1 . A method for treating cancer in a subject, the method comprising the step of administering to the subject an auristatin-based antibody-drug conjugate and an AKT inhibitor, wherein cells of the cancer express a cell-surface antigen internalizable on selective binding by the antibody of the auristatin-based antibody-drug conjugate and wherein the cells are characterized by constitutive activation of AKT of the PI3K-AKT-mTOR pathway, wherein the auristatin-based antibody drug conjugate and the AKT inhibitor act synergistically in killing cancer cells in an in vitro or animal model of the cancer, wherein the AKT inhibitor is perifosine, MK2206, VQD-002, XL418, or PX316.

2 . The method of claim 1 , wherein the auristatin-based antibody-drug conjugate has the following formula:
L-(LU-D) p   (I)
or a pharmaceutically acceptable salt thereof; wherein: L is the antibody that selectively binds to the internalizable cancer cell antigen expressed on the surface of the cancer cell; and (LU-D) is a drug-linker moiety, wherein: LU- is a Linker unit; -D is an auristatin having cytostatic or cytotoxic activity against the target cells; and subscript p ranges from 1 to 20.

3 . The method of claim 2 wherein the auristatin has the formula:

or a pharmaceutically acceptable salt form thereof.

4 . The method of claim 2 , wherein the auristatin has the formula:

or a pharmaceutically acceptable salt form thereof.

5 . The method of claim 2 wherein the Linker Unit has the formula:
—A a —W w —Y y —

or a pharmaceutically acceptable salt form thereof,
wherein:
—A— is a Stretcher Unit;
subscript a is 0 or 1;
each —W— is independently an Amino Acid Unit;
subscript w is an integer ranging from 0 to 12;
—Y— is a Spacer unit; and
subscript y is 0, 1 or 2.

6 . The method of claim 5 , wherein the auristatin-based antibody drug conjugate has the formula:

or a pharmaceutically acceptable salt form thereof.

7 . The method of claim 5 , wherein the auristatin-based antibody drug conjugate has the formula:

or a pharmaceutically acceptable salt form thereof.

8 . The method of claim 7 , wherein the auristatin-based antibody drug conjugate has the formula

or a pharmaceutically acceptable salt form thereof.

9 . The method of claim 8 , wherein the auristatin-based antibody-drug conjugate has the formula:

or a pharmaceutically acceptable salt form thereof, wherein mAb is a monoclonal antibody, S is a sulfur atom of the antibody, and subscript p ranges from 1 to 8.

10 . The method of claim 2 , wherein the auristatin-based antibody-drug conjugate has the formula:

or a pharmaceutically acceptable salt form thereof.

11 . The method of claim 10 , wherein the auristatin-based antibody-drug conjugate has the formula:

or a pharmaceutically acceptable salt form thereof wherein mAb is a monoclonal antibody, S is a sulfur atom of the antibody, and subscript p ranges from 1 to 8.

12 . The method of claim 2 , wherein the administered auristatin-based antibody-drug conjugate is in a composition comprising a collection of such conjugates in which the average number of drug molecules per antibody ranges from about 2 to about 6.

13 . The method of claim 1 , wherein the antigen is CD19, CD30 or CD70 and the cancer is a hematological malignancy expressing CD19, CD30 or CD70 or renal cell carcinoma expressing CD70.

Assignees

• Seagen Inc

Inventors

• Lewis Timothy S
• Law Che-Leung
• Mcearchern Julie A

Classifications

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/498

  Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine · CPC title

• A61K31/4745

  condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title